| Revenue | DKK 1,5M | +38% |
| EBITDA | DKK 81K | +122% |
| Net profit | DKK 52K | +90% |
| Total assets | DKK 581K | +50% |
| Equity | DKK 177K | +1% |
| Employees | 2 | — |
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | -3 | -8 | 4 | -1 | 10 | 13 | 535 | 1.053 | 1.457 |
| Staff expenses | -0 | -0 | -0 | -0 | -0 | -0 | -523 | -1.017 | -1.377 |
| EBITDA | -3 | -8 | 4 | -1 | 10 | 13 | 12 | 36 | 81 |
| Depreciation & amort. | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 |
| EBIT | -3 | -8 | 4 | -1 | 10 | 13 | 12 | 36 | 81 |
| Net financials | 10 | -3 | 1 | 1 | -3 | -2 | -0 | -2 | -14 |
| Profit before tax | 7 | -11 | 5 | 0 | 7 | 11 | 12 | 35 | 66 |
| Tax | 2 | -2 | 1 | 0 | 1 | 2 | 3 | 8 | 15 |
| Net profit | 5 | -9 | 4 | 0 | 5 | 9 | 9 | 27 | 52 |
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|
| Total assets | 207 | 128 | 141 | 133 | 364 | 150 | 272 | 388 | 581 |
| Equity | 130 | 121 | 125 | 126 | 131 | 140 | 148 | 175 | 177 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 78 | 7 | 16 | 7 | 233 | 11 | 123 | 212 | 404 |
| Total debt | 78 | 7 | 16 | 7 | 233 | 11 | 123 | 212 | 404 |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
MM Management | Management | 2021 | — | — |
LZ Management | Management | 2016 | — | — |
No data on file.
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
PHARMA NORD ApS | Company | 100.0% | 100.0% | 2016 |
| Person | Role here | Other companies |
|---|---|---|
| Michael Maul Svarrer | Management | 0 companies |
| Leo Zingenberg | Management | 0 companies |